Ginkgo Bioworks
DNA
165 hedge funds and large institutions have $319M invested in Ginkgo Bioworks in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 42 increasing their positions, 39 reducing their positions, and 27 closing their positions.
290% more call options, than puts
Call options by funds: $29.6M | Put options by funds: $7.59M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
49% more capital invested
Capital invested by funds: $214M → $319M (+$104M)
33% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 27
10.82% more ownership
Funds ownership: 61.1% → 71.91% (+11%)
4% more funds holding
Funds holding: 158 → 165 (+7)
8% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$28.6M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$14.9M |
| 3 |
JMFC
J.M. Forbes & Co
Boston,
Massachusetts
|
+$4.94M |
| 4 |
Millennium Management
New York
|
+$4.49M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.08M |
| 2 |
Legal & General Group
London,
United Kingdom
|
-$4.93M |
| 3 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$3.98M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.8M |
| 5 |
GCM
Glenview Capital Management
New York
|
-$2.46M |
DNA Hedge Fund Activity: Q4 2024 in Review
165 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q4 2024, worth a combined $319M — up 49% from $214M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new DNA positions and 27 closed out — a net gain of 9 holders — while 42 added to existing stakes and 39 trimmed.
The largest buyer was Bank of America, adding an estimated $28.6M. The largest seller was Vanguard Group, cutting an estimated $5.08M.
- 165 institutional investors held Ginkgo Bioworks (DNA) as of Q4 2024, up from 158 in Q3 2024.
- Funds reported $319M of Ginkgo Bioworks stock for Q4 2024, up 49% quarter-over-quarter.
- 36 funds opened new Ginkgo Bioworks positions in Q4 2024 and 27 closed out, a net change of +9 holders.
- The largest Ginkgo Bioworks buyer in Q4 2024 was Bank of America, an estimated $28.6M added.
- The largest Ginkgo Bioworks seller in Q4 2024 was Vanguard Group, an estimated $5.08M sold.
Based on aggregated 13F filings for Q4 2024.